NCT Number stringlengths 11 11 | Study Title stringlengths 7 300 | Study URL stringlengths 44 44 | Acronym stringlengths 1 14 ⌀ | Study Status stringclasses 15
values | Brief Summary stringlengths 2 5k ⌀ | Study Results stringclasses 3
values | Conditions stringlengths 1 11.1k ⌀ | Interventions stringlengths 4 3.06k ⌀ | Primary Outcome Measures stringlengths 2 134k ⌀ | Secondary Outcome Measures stringlengths 2 184k ⌀ | Other Outcome Measures stringlengths 11 111k ⌀ | Sponsor stringlengths 2 146 ⌀ | Collaborators stringlengths 2 7.48k ⌀ | Sex stringclasses 4
values | Age stringclasses 7
values | Phases stringclasses 8
values | Enrollment float64 0 189M ⌀ | Funder Type stringclasses 10
values | Study Type stringclasses 4
values | Study Design stringlengths 4 178 ⌀ | Other IDs stringlengths 1 1.82k ⌀ | Start Date stringlengths 7 10 ⌀ | Primary Completion Date stringlengths 7 10 ⌀ | Completion Date stringlengths 7 10 ⌀ | First Posted stringlengths 10 10 ⌀ | Results First Posted stringlengths 10 10 ⌀ | Last Update Posted stringlengths 10 183 | Locations stringlengths 10 183k ⌀ | Study Documents stringlengths 85 1.2k ⌀ | Processed_Interventions stringlengths 2 1.57M |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
NCT00072579 | Sargramostim in Treating Patients With Chronic Phase Chronic Myelogenous Leukemia Who Are Not in Complete Cytogenetic Remission Following Initial Treatment | https://clinicaltrials.gov/study/NCT00072579 | null | COMPLETED | RATIONALE: Colony-stimulating factors, such as sargramostim, may increase the number of immune cells found in bone marrow or peripheral blood and may bring about complete remission in patients who have chronic phase chronic myelogenous leukemia.
PURPOSE: This phase II trial is studying sargramostim to see how well it ... | NO | Leukemia | BIOLOGICAL: sargramostim | Cytogenetic response (complete and partial) | Toxicity as assessed by the Expanded Common Toxicity Criteria v2.0|Time to progression|Survival | null | Wake Forest University Health Sciences | National Cancer Institute (NCI) | ALL | ADULT, OLDER_ADULT | PHASE2 | null | OTHER | INTERVENTIONAL | Allocation: |Intervention Model: |Masking: NONE|Primary Purpose: TREATMENT | CCCWFU-23102|CDR0000340983|BRLX-02153|NCI-7350 | 2003-05 | 2006-04 | 2007-12 | 2003-11-05 | null | 2017-01-19 | CCOP - Western Regional, Arizona, Phoenix, Arizona, 85006-2726, United States|CCOP - Bay Area Tumor Institute, Oakland, California, 94609-3305, United States|CCOP - Mount Sinai Medical Center, Miami Beach, Florida, 33140, United States|Regional Radiation Oncology Center at Rome, Rome, Georgia, 30165, United States|CCOP... | null | {
"Sargramostim": [
{
"intervention_type": "BIOLOGICAL",
"description": "sargramostim",
"name": "Sargramostim",
"synonyms": [
"",
"rGM-CSF",
"Recombinant human granulocyte-macrophage colony stimulating factor",
"Granulocyte-Macrophage Colony-Stimulating Fact... |
NCT00517179 | Effect of Vardenafil on Blood Pressure in Patients With Erectile Dysfunction Who Received Concomitant Doxazosin GITS | https://clinicaltrials.gov/study/NCT00517179 | null | COMPLETED | The purpose of this study is to investigate the interaction between doxazosin GITS and vardenafil on blood pressure (Both systolic and diastolic blood pressure) in patients with both ED and BPH. | NO | Prostatic Hyperplasia|Impotence | DRUG: Vardenafil 10mg | Mean maximal change of the standing systolic blood pressure (SBP) from half hour prior to till six hour after administration of the drug (baseline) with vardenafil administration versus placebo, From half hour prior to till six hour after administration of the drug (baseline) | Mean maximal post-baseline change of the standing and supine diastolic blood pressure (DBP), From half hour prior to till six hour after administration of the drug (baseline)|Mean maximal post-baseline change supine SBP, and (3) the pattern of changes of the SBP and DBP from half hour prior to till six hours after admi... | null | Hospital Authority, Hong Kong | null | MALE | ADULT, OLDER_ADULT | null | 40 | OTHER_GOV | INTERVENTIONAL | Allocation: RANDOMIZED|Intervention Model: CROSSOVER|Masking: DOUBLE|Primary Purpose: TREATMENT | CRE-2006.017-T|HARECCTR0500057 | 2006-04 | null | 2007-05 | 2007-08-16 | null | 2011-06-16 | Prince of Wales Hospital, Hong Kong, China | null | {
"Vardenafil": [
{
"intervention_type": "DRUG",
"description": "Vardenafil 10mg",
"name": "Vardenafil",
"synonyms": [
"Levitra",
"Vardenafilo",
"Vardenafil",
"Vard\u00e9nafil",
"Vardenafilum"
],
"medline_plus_id": "a603035",
"gener... |
NCT00812279 | Investigate the Exposure to Selected Smoke Constituents in Smokers Switching to Distillation Based Smoking Article | https://clinicaltrials.gov/study/NCT00812279 | null | COMPLETED | The overall purpose of this clinical study conducted in confinement under well-defined conditions is to obtain initial data on the levels of human body exposure to selected smoked constituents of the SMAR cigarette.
The main objective of this study is to compare the biomarkers of exposure to cigarette smoke constituen... | NO | Smoking | OTHER: Distillation based smoking article (SMAR cigarette)|OTHER: conventional cigarette|OTHER: smoking cessation | To demonstrate a reduction in the three primary biomarkers of exposure: Carboxyhaemoglobin concentration in blood, Urinary excretion of S-phenylmercapturic acid and urinary excretion of NNAL and NNAL-glucuronides (total NNAL), 5 days | To explore changes from baseline COHb, S-PMA, and total NNAL in the three study arms in the course of the study, 5 days|To explore changes from baseline in the three study arms with regard to urinary excretion of biomarkers of exposure to several other smoke constituents., 5 days|To assess urinary excretion of nicotine... | null | Philip Morris Products S.A. | null | ALL | ADULT | null | 112 | INDUSTRY | INTERVENTIONAL | Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: BASIC_SCIENCE | YVD-CS01-EU | 2008-11 | 2009-02 | 2009-02 | 2008-12-22 | null | 2019-11-07 | MTZ Clinical Research Inc., Warsaw, 02-106, Poland | null | {
"Distillation based smoking article (SMAR cigarette)": [
{
"intervention_type": "OTHER"
}
],
"conventional cigarette": [
{
"intervention_type": "OTHER"
}
],
"smoking cessation": [
{
"intervention_type": "OTHER"
}
]
} |
NCT03878979 | Preoperative Immune Checkpoint Inhibitor for Patients With Primary Untreated or Recurrent/Metastatic SCCHN | https://clinicaltrials.gov/study/NCT03878979 | null | COMPLETED | Nivolumab (also known as BMS-936558) before surgery to people with newly diagnosed or recurrent squamous cell carcinoma of head and neck (SCCHN). | NO | Head and Neck Squamous Cell Carcinoma|Head and Neck Cancer|Head and Neck Cancer Metastatic | DRUG: Nivolumab 480mg and surgical resection | Safety as measured by number of participants with drug-related adverse events, Safety of neoadjuvant nivolumab administration in patients with newly diagnosed head and neck cancer and those with locoregional recurrence or oligometastatic disease undergoing surgical resection measured by number of participants with drug... | Major pathologic response rate, Number of participants with < 10% residual tumor in the resection specimen., Day 0 (after surgery)|Progression free survival (PFS), Number of months until radiologic or clinical progression or death, whichever occurs first., up to 3 years|Radiographic response rate, Number of participant... | null | Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins | Bristol-Myers Squibb | ALL | ADULT, OLDER_ADULT | PHASE2 | 26 | OTHER | INTERVENTIONAL | Allocation: NON_RANDOMIZED|Intervention Model: PARALLEL|Masking: SINGLE (PARTICIPANT)|Primary Purpose: TREATMENT | J1923|IRB00207577|CA209-9H7 | 2019-07-08 | 2023-10-17 | 2023-10-17 | 2019-03-18 | null | 2024-02-20 | Johns Hopkins Sidney Kimmel Comprehensive Cancer Center, Baltimore, Maryland, 21287, United States | null | {
"Nivolumab": [
{
"intervention_type": "DRUG",
"description": "Nivolumab 480mg and surgical resection",
"name": "Nivolumab",
"synonyms": [
"ONO-4538",
"MDX 1106",
"MDX-1106",
"ONO 4538",
"ONO4538",
"BMS936558",
"Opdivo",
"Niv... |
NCT05602779 | Leverage Noninvasive Transcutaneous Vagus Nerve Stimulation to Reduce Suicidal Behaviors in Vulnerable Adolescents | https://clinicaltrials.gov/study/NCT05602779 | null | RECRUITING | Suicidal thoughts, suicide attempts, and suicide are increasingly common in adolescence.
Current face-to-face prevention approaches are of limited effectiveness, rely on extensive resources, and are at odds with adolescents digital preferences. We will evaluate two unconventional but promising interventions delivered ... | NO | Self Harm|Suicidal Ideation | DEVICE: tVns Program|OTHER: Phone App Program|COMBINATION_PRODUCT: tVNS and Phone App Program|OTHER: Enhanced Treatment as Usual | Change from Baseline in Non-Suicidal Self Injury Behaviors at 30 Days, Teens will be assessed at the baseline lab visit for emotion regulation and self-harm through questions on the Qualtrics survey (measures are Difficulties in Emotion Regulation Scale and the Youth Self Report). They will also complete a face-to-face... | Adherence to tVNS and Phone App intervention from Baseline to 30 days., Using data from the Xen device and the phone app, we will be able to determine the number of occurances the device and app were accessed, as well as for how much time each was actively used. Participants will also report on acceptability, obtrusive... | null | University of Notre Dame | University of Rochester | ALL | CHILD | null | 212 | OTHER | INTERVENTIONAL | Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: SINGLE (PARTICIPANT)|Primary Purpose: PREVENTION | 22-08-7372 | 2023-10-08 | 2027-04-15 | 2027-09-30 | 2022-11-02 | null | 2023-12-06 | University of Notre Dame, South Bend, Indiana, 46617, United States | null | {
"tVns Program": [
{
"intervention_type": "DEVICE"
}
],
"Phone App Program": [
{
"intervention_type": "OTHER"
}
],
"tVNS and Phone App Program": [
{
"intervention_type": "COMBINATION_PRODUCT"
}
],
"Enhanced Treatment as Usual": [
{
"intervention_type": ... |
NCT01126879 | Genistein in Treating Patients With Prostate Cancer | https://clinicaltrials.gov/study/NCT01126879 | null | TERMINATED | RATIONALE: Genistein may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth.
PURPOSE: This randomized phase II trial is studying how well genistein works in treating patients with prostate cancer. | YES | Adenocarcinoma of the Prostate|Recurrent Prostate Cancer|Stage I Prostate Cancer|Stage II Prostate Cancer|Stage III Prostate Cancer | DIETARY_SUPPLEMENT: genistein|OTHER: placebo|PROCEDURE: therapeutic conventional surgery | Number of Circulating Prostate Cells (CPCs) in the Blood as Determined by qRT-PCR for PSA on RNA Extracted From PBMNCs, Blood will be collected to analyze the number of CPCs at screening, after 1-month of treatment, at surgery and at 1 and 12 months after surgery., At screening, after 1-month of treatment, at surgery a... | Natural History of Circulating Prostate Cells (CPCs) in a Cohort of Subjects Prior to and Post Radical Prostatectomy, Blood will be drawn to analyze the natural history of circulating prostate cells (CPCs) in a cohort of subjects at baseline and 1 and 12 months after surgery., At baseline, 1 and 12 months after surgery... | null | Northwestern University | National Cancer Institute (NCI) | MALE | ADULT, OLDER_ADULT | PHASE2 | 12 | OTHER | INTERVENTIONAL | Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: DOUBLE (PARTICIPANT, INVESTIGATOR)|Primary Purpose: TREATMENT | NCI 09U2|NCI-2010-00941|STU00019487|P50CA090386 | 2011-02-03 | 2013-05-09 | 2013-12-28 | 2010-05-20 | 2019-07-02 | 2019-09-10 | Northwestern University, Chicago, Illinois, 60611, United States | null | {
"genistein": [
{
"intervention_type": "DIETARY_SUPPLEMENT"
}
],
"placebo": [
{
"intervention_type": "OTHER"
}
],
"therapeutic conventional surgery": [
{
"intervention_type": "PROCEDURE"
}
]
} |
NCT05865379 | Efficacy and Safety of BUFY01 Versus SVS20 in the Treatment of Dry Eye Disease | https://clinicaltrials.gov/study/NCT05865379 | BUSTON-01 | NOT_YET_RECRUITING | The goal of this interventional investigation is to compare BUFY01 with SVS20 in the treatment of patients with dry eye disease. The main questions it aims to answer are:
* Is BUFY01 non-inferior to SVS20 in terms of signs of DED?
* Is BUFY01 non-inferior to SVS20 in terms of symptoms of DED?
Participants will be ask... | NO | Dry Eye Disease | DEVICE: BUFY01 eye drops in single-dose containers|DEVICE: SVS20 eye drops in single-dose containers | Signs, Change from baseline in Oxford score (0-15, a higher score meaning a worse outcome), Day 28 | Symptoms, Change from baseline in Ocular Surface Disease Index, Day 28 | null | TRB Chemedica International SA | null | ALL | ADULT, OLDER_ADULT | null | 80 | INDUSTRY | INTERVENTIONAL | Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: QUADRUPLE (PARTICIPANT, CARE_PROVIDER, INVESTIGATOR, OUTCOMES_ASSESSOR)|Primary Purpose: TREATMENT | BUFY01-CT-2101 | 2024-03 | 2025-10 | 2025-10 | 2023-05-18 | null | 2023-11-24 | null | null | {
"BUFY01 eye drops in single-dose containers": [
{
"intervention_type": "DEVICE"
}
],
"SVS20 eye drops in single-dose containers": [
{
"intervention_type": "DEVICE"
}
]
} |
NCT03791879 | Caudal Dexmedetomidine Analgesia in Pediatrics . | https://clinicaltrials.gov/study/NCT03791879 | null | COMPLETED | Dexmedetomidine (DEXM) is a highly selective α2-adrenoceptor agonist that has been used increasingly in pediatric anesthesia. This prospective double blinded randomized comparative study is designed to evaluate the analgesic effect of caudal increasing doses of DEXM 0.5 , 1 , 1.5 , 2µg/kg combined with Levobupivacaine ... | NO | 164 Boys for Hypospadias Surgery Under General Anesthesia With Caudal Block | DRUG: Caudal dexamedatomidine analgesia | Time to (1st analgesic request objective pain score (OPS) ≥4), time from full recovery till child express moderate pain OPS 4 and ask for the first analgesic dose, Basal (0) till 24 hours. | null | null | Mansoura University | null | MALE | CHILD | null | 164 | OTHER | INTERVENTIONAL | Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: TRIPLE (PARTICIPANT, CARE_PROVIDER, OUTCOMES_ASSESSOR)|Primary Purpose: SUPPORTIVE_CARE | MFM IR.18.11.322 - 2018/11/11 | 2019-01-01 | 2020-10-01 | 2020-10-15 | 2019-01-03 | null | 2021-03-01 | Anesthesia department,Faculty of medicine, Mansoura univerisety, Mansoura, Egypt | null | {
"Caudal dexamedatomidine analgesia": [
{
"intervention_type": "DRUG"
}
]
} |
NCT03877679 | The Effect of Topical Curcumin Versus Topical Corticosteroid on Management of Oral Lichen Planus Patients | https://clinicaltrials.gov/study/NCT03877679 | null | UNKNOWN | Introduce a new anti-inflammatory and antioxidant paste preparation (curcumin paste) in the management of Oral lichen planus.
* Assess the efficacy of this preparation on pain, clinical parameter and the level of IL-33 in saliva.
* Compare the outcome of new preparation with the gold standard treatment (corticosteroid... | NO | Oral Lichen Planus | DRUG: Triamcinolone|DRUG: Turmeric paste | Pain intensity, measured by Visual Analog Scale (VAS) 0 = no pain 10= severe pain 0= no pain 10= pain severe pain, 4 weeks | clinical sign score, measured by Thongprasom from score 0 to 5 0= only white lesion 5=area of erosion more than 2 cm, Baseline , 2nd week and 4th week|IL-33 level in saliva, by ELISA, base line and 4th week | null | Cairo University | null | ALL | CHILD, ADULT, OLDER_ADULT | PHASE1 | 40 | OTHER | INTERVENTIONAL | Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: SINGLE (OUTCOMES_ASSESSOR)|Primary Purpose: TREATMENT | OMED2:5:1 | 2019-05-01 | 2020-05-01 | 2020-06-01 | 2019-03-18 | null | 2019-03-18 | null | null | {
"Triamcinolone": [
{
"intervention_type": "DRUG",
"description": "Triamcinolone",
"name": "Triamcinolone",
"synonyms": [
"Triamcinolona",
"Triacort",
"Aristogel",
"9-fluoro-11\u03b2,16\u03b1,17,21-tetrahydroxypregna-1,4-diene-3,20-dione",
"Fluoxypr... |
NCT03960879 | DNA Methylation for Screening Uterine Cervical Lesions | https://clinicaltrials.gov/study/NCT03960879 | null | UNKNOWN | The primary objective of this study is to compare the testing of DNA methylation, high-risk HPV subtypes, and cytology with the definite histological results for uterine cervical lesions in a prospective cohort study.
This study will include 300 unselected patients with definite histological results. All the cervical ... | NO | DNA Methylation|Uterine Cervical Cancer|High Grade Squamous Intraepithelial Lesions|Low Grade Squamous Intraepithelial Lesions | DIAGNOSTIC_TEST: DNA methylation|DIAGNOSTIC_TEST: High-risk HPV|DIAGNOSTIC_TEST: TCT | Sensitivity of DNA methylation, Sensitivity of DNA methylation compared with histological results for the differentiation of cervical cancer and high grade squamous intraepithelial lesions (HSIL), 1 year|Specificity of DNA methylation, Specificity of DNA methylation compared with histological results for the differenti... | Positive predictive value of DNA methylation, Positive predictive value of DNA methylation compared with histological results for the differentiation of cervical cancer and HSIL, 1 year|Negative predictive value of DNA methylation, Negative predictive value of DNA methylation compared with histological results for the ... | null | Lei Li | null | FEMALE | ADULT, OLDER_ADULT | null | 300 | OTHER | OBSERVATIONAL | Observational Model: |Time Perspective: p | METHY2 | 2019-06-01 | 2020-06-01 | 2020-06-01 | 2019-05-23 | null | 2019-05-24 | Lei Li, Beijing, Beijing, 100730, China | null | {
"DNA methylation": [
{
"intervention_type": "DIAGNOSTIC_TEST"
}
],
"Human Papillomavirus (HPV) Vaccine (Cervarix)": [
{
"intervention_type": "DIAGNOSTIC_TEST",
"description": "High-risk HPV",
"name": "Human Papillomavirus (HPV) Vaccine (Cervarix)",
"synonyms": [
... |
NCT02385279 | Study Comparing the MiStent SES Versus the XIENCE EES Stent | https://clinicaltrials.gov/study/NCT02385279 | DESSOLVE III | COMPLETED | The primary objective of this study is to compare the performance of MISTENT to that of XIENCE in an all-comers patient population with symptomatic ischemic heart disease. The patients will be followed through 3 years for major clinical events. | YES | Coronary Stenosis | DEVICE: MiStent|DEVICE: XIENCE EES | Number of Participants With Occurrence of a Device Oriented Composite Endpoint (DOCE), DOCE is a composite of clinical endpoint of cardiac death, myocardial infarction not clearly attributable to a non-target vessel and clinically-indicated target lesion revascularization., 12 months postprocedure | POCE, POCE defined as all-cause death, any Myocardial Infarction (MI), or any revascularization, At 12 months|MACE, MACE defined as all-cause death, any MI, or any Target Vessel Revascularization (TVR), At 12 months|Target Vessel Failure (TVF), Target Vessel Failure (TVF) defined as cardiac death, TV MI, or clinically ... | null | ECRI bv | Micell Technologies|Stentys | ALL | ADULT, OLDER_ADULT | null | 1,398 | INDUSTRY | INTERVENTIONAL | Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: SINGLE (PARTICIPANT)|Primary Purpose: TREATMENT | ECRI-005 | 2015-03-20 | 2017-01-31 | 2021-02-04 | 2015-03-11 | 2023-05-08 | 2023-05-08 | Research Center Corbeil, Corbeil, France|Research Center Nimes, Nimes, France|Research Center Poitiers, Poitiers, France|Research Center Jena, Jena, Germany|Research Center Leipzig, Leipzig, Germany|Research Center Munster, Munster, Germany|Research Center Ulm, Ulm, Germany|Research Center Wiesbaden, Wiesbaden, Germany... | Study Protocol and Statistical Analysis Plan, https://cdn.clinicaltrials.gov/large-docs/79/NCT02385279/Prot_SAP_000.pdf | {
"MiStent": [
{
"intervention_type": "DEVICE"
}
],
"Erythromycin": [
{
"intervention_type": "DEVICE",
"description": "XIENCE EES",
"name": "Erythromycin",
"synonyms": [
"Erycette",
"Tiloryth",
"T-Stat",
"PCE",
"Phosphate, Erythromy... |
NCT04128579 | Study of EQ001 (Itolizumab) in Systemic Lupus Erythematosus With or Without Active Proliferative Nephritis | https://clinicaltrials.gov/study/NCT04128579 | EQUALISE | COMPLETED | This is a multi-center study to evaluate the safety, tolerability, PK, PD, and clinical activity of itolizumab (EQ001) in subjects with Systemic Lupus Erythematosus with or without Active Proliferative Lupus Nephritis | NO | Lupus Erythematosus|Lupus Nephritis | DRUG: Itolizumab [Bmab 600] | Incidence of Treatment Emergent Adverse Events, Number of participants with treatment-related adverse events as assessed by the Common Terminology Criteria for Adverse Events (CTCAE) v5.0., Type A up to Day 57 or Type B up to Day 253 | To characterize the PK of itolizumab, To characterize the pharmacokinetics of itolizumab, Type A up to Day 57 or Type B up to Day 253|CD6 receptor occupancy, the % levels of free versus EQ001-bound CD6 receptor on T cells, Type A up to Day 57 or Type B up to Day 253 | null | Equillium | Biocon Limited | ALL | ADULT, OLDER_ADULT | PHASE1 | 55 | INDUSTRY | INTERVENTIONAL | Allocation: NON_RANDOMIZED|Intervention Model: SEQUENTIAL|Masking: NONE|Primary Purpose: TREATMENT | EQ001-19-002 | 2019-10-01 | 2023-11-16 | 2024-01-18 | 2019-10-16 | null | 2024-02-28 | AKDHC Medical Research Services, LLC, Sun City, Arizona, 85351, United States|California Institute of Renal Research, Chula Vista, California, 91910, United States|University of California San Diego Perlman Ambulatory Clinic, La Jolla, California, 92037, United States|Clinical Research of West Florida - Clearwater, Cle... | null | {
"Itolizumab": [
{
"intervention_type": "DRUG",
"description": "Itolizumab [Bmab 600]",
"name": "Itolizumab",
"synonyms": [
"Itolizumab"
],
"drugbank_id": "DB16207",
"generic_names": [
"Itolizumab"
]
}
]
} |
NCT03793179 | Testing the Timing of Pembrolizumab Alone or With Chemotherapy as First Line Treatment and Maintenance in Non-small Cell Lung Cancer | https://clinicaltrials.gov/study/NCT03793179 | null | ACTIVE_NOT_RECRUITING | This phase III trial studies whether pembrolizumab alone as a first-line treatment, followed by pemetrexed and carboplatin with or without pembrolizumab after disease progression is superior to induction with pembrolizumab, pemetrexed and carboplatin followed by pembrolizumab and pemetrexed maintenance in treating pati... | NO | Lung Non-Squamous Non-Small Cell Carcinoma|Stage IIIB Lung Cancer AJCC v8|Stage IIIC Lung Cancer AJCC v8|Stage IV Lung Cancer AJCC v8 | PROCEDURE: Biospecimen Collection|DRUG: Carboplatin|PROCEDURE: Computed Tomography|PROCEDURE: Magnetic Resonance Imaging|BIOLOGICAL: Pembrolizumab|DRUG: Pemetrexed|PROCEDURE: Positron Emission Tomography | Overall survival (OS), OS distributions will be estimated using the Kaplan-Meier method., From randomization to death from any cause, assessed up to 5 years post treatment | Progression-free survival (PFS), PFS distributions will be estimated using the Kaplan-Meier method., From randomization to documented disease progression or death from any cause, assessed up to 5 years post treatment|Best objective response, Best objective response will be evaluated via Response Evaluation Criteria in ... | null | National Cancer Institute (NCI) | null | ALL | ADULT, OLDER_ADULT | PHASE3 | 600 | NIH | INTERVENTIONAL | Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: TREATMENT | NCI-2018-03695|NCI-2018-03695|EA5163|EA5163|U10CA180820 | 2019-04-05 | 2028-12-31 | 2028-12-31 | 2019-01-04 | null | 2024-06-17 | University of South Alabama Mitchell Cancer Institute, Mobile, Alabama, 36688, United States|Anchorage Associates in Radiation Medicine, Anchorage, Alaska, 98508, United States|Anchorage Radiation Therapy Center, Anchorage, Alaska, 99504, United States|Alaska Breast Care and Surgery LLC, Anchorage, Alaska, 99508, Unite... | null | {
"Biospecimen Collection": [
{
"intervention_type": "PROCEDURE"
}
],
"Carboplatin": [
{
"intervention_type": "DRUG",
"description": "Carboplatin",
"name": "Carboplatin",
"synonyms": [
"Carboplatino",
"Carboplatin",
"cis-diammine(1,1-cyclobutanedic... |
NCT02312479 | Safety and Performance Study of the Nyxoah SAT System for Treating OSA | https://clinicaltrials.gov/study/NCT02312479 | null | TERMINATED | A prospective open-label, single treatment study to assess the safety and the performance of the Nyxoah SAT system for the treatment of Obstructive Sleep Apnea | NO | Obstructive Sleep Apnea | DEVICE: Nyxoah SAT system | Incidence of serious device related adverse events, 6-months post-implantation|Mean change of AHI (Apnea-Hypopnea Index) measured by in-lab polysomnography (PSG) from baseline measurement to 6-months post-implantation, 6-months post-implantation | null | null | Nyxoah S.A. | null | ALL | ADULT, OLDER_ADULT | null | 6 | INDUSTRY | INTERVENTIONAL | Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: TREATMENT | SAT2014A | 2014-12 | 2015-11 | 2016-04 | 2014-12-09 | null | 2016-09-27 | Antwerp University Hospital, Edegem, Belgium|Universitäts-HNO-Klinik Mannheim, Mannheim, Germany | null | {
"Nyxoah SAT system": [
{
"intervention_type": "DEVICE"
}
]
} |
NCT04236479 | Mesenchymal Stromal Cells for Infants With Congenital Heart Disease (MedCaP) | https://clinicaltrials.gov/study/NCT04236479 | null | ACTIVE_NOT_RECRUITING | The proposed study will be a prospective, open-label, single-center, safety and feasibility phase 1 trial of allogeneic bone marrow-derived mesenchymal stromal cell (BM-MSC) delivery though cardiopulmonary bypass (CPB) using a homogeneous population of infants with congenital heart disease (CHD) who will be undergoing ... | NO | Congenital Heart Disease (CHD) | BIOLOGICAL: BM-MSC | Number of subjects who experience serious adverse events, adverse events, and/or early treatment discontinuations., Dose Limiting Toxicity is attributable to the MSC administration., 45 days following the MSC administration | Actual magnitude of differences in neuroimaging and neurodevelopmental variables will be measured after MSC delivery., Secondary objective will be measured by using the Pediatric Cardiac Critical Care Consortium (PC4) registry system., 18 months | null | Catherine Bollard | null | ALL | CHILD | PHASE1 | 17 | OTHER | INTERVENTIONAL | Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: TREATMENT | Pro00011914 | 2020-07-29 | 2024-09 | 2025-04 | 2020-01-22 | null | 2023-09-21 | Childrens National Health System, Washington, District of Columbia, 20010, United States | null | {
"BM-MSC": [
{
"intervention_type": "BIOLOGICAL"
}
]
} |
NCT03468179 | Oatmeal Effect on N-acyl-phosphatidylethanolamines | https://clinicaltrials.gov/study/NCT03468179 | NAPE | COMPLETED | N-acyl-phosphatidylethanolamine (NAPEs) and their active metabolites, N-acyl-ethanolamides (NAEs) are lipid satiety factors that are normally biosynthesized in the intestinal tract in response to food intake. Reduced levels of NAPEs and NAEs have been found in obese individuals, and increasing plasma NAPE and NAEs leve... | YES | Obesity|Cardiovascular Diseases | DIETARY_SUPPLEMENT: Oatmeal | Change in Serum N-acyl-phosphatidylethanolamine (NAPE), Change in serum NAPE from baseline to 120 minutes post-oatmeal challenge, Baseline to 120 minutes | Serum NAPE, Serum NAPE Levels at 30, 60, and 90 minutes, 30, 60, and 90 minutes|Serum N-acyl-ethanolamides (NAE), Serum NAE levels at baseline, 30, 60, 90 and 120 minutes, baseline 30, 60, 90 and 120 minutes | null | Vanderbilt University Medical Center | null | ALL | ADULT, OLDER_ADULT | null | 10 | OTHER | INTERVENTIONAL | Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: BASIC_SCIENCE | JJWPending | 2018-10-07 | 2018-12-31 | 2018-12-31 | 2018-03-16 | 2019-12-13 | 2019-12-13 | Vanderbilt University Medical Center, Nashville, Tennessee, 37232, United States | Informed Consent Form, https://cdn.clinicaltrials.gov/large-docs/79/NCT03468179/ICF_000.pdf|Study Protocol and Statistical Analysis Plan, https://cdn.clinicaltrials.gov/large-docs/79/NCT03468179/Prot_SAP_001.pdf | {
"Oatmeal": [
{
"intervention_type": "DIETARY_SUPPLEMENT"
}
]
} |
NCT02328079 | Steroid-Antiviral Treatment in Rehabilitation of Facial Palsy | https://clinicaltrials.gov/study/NCT02328079 | null | COMPLETED | The purpose of this study is to assess the efficacy of antiviral medicine (acyclovir) in recovery of complete facial Palsy. Fifty patients (Males and females) with acute Facial Palsy within the first 3 days of onset with age ranged from 15-60 years old. Each patient was submitted to the following clinical evaluation us... | NO | Facial Palsy | DRUG: Steroids (Prednisolone) and Steroids plus Antiviral (Prednisolone + acyclovir) | Facial muscle function using clinical scale, Evaluations of facial muscle function using clinical scale were performed blindly by a neurologist who was unaware of the type of treatment of which the patient had received, 2 months | Nerve conduction study of facial nerve., Measurment of facial n. coduction, 2 months | null | Assiut University | null | ALL | CHILD, ADULT | null | 50 | OTHER | INTERVENTIONAL | Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: TREATMENT | Antiviral in facial palsy | 2013-04 | 2014-11 | 2014-11 | 2014-12-31 | null | 2020-09-16 | null | null | {
"Steroids (Prednisolone) and Steroids plus Antiviral (Prednisolone + acyclovir)": [
{
"intervention_type": "DRUG"
}
]
} |
NCT01801579 | Reproducibility of Ankle Brachial Index After Maximal Exercise | https://clinicaltrials.gov/study/NCT01801579 | RICATEM | COMPLETED | Hemodynamic changes in the lower limbs are very important and rapid after maximal exercise. The automatic method allows a fastest measurement of the Ankle-Brachial Index (ABI). Thus, it appears important to know whether automatic assessment of ABI is as reliable and reproducible as the manual method. | NO | Normal Subjects | null | Test-retest difference in ankle to brachial pressure index, Comparison of differendces observed on test-retest measures with manual and automatic measurements, up to 2 week | Duration of recordings., Comaprison of the time needed to complete the recording with automatic vs. manual techniques, up to 2 weeks | null | University Hospital, Angers | Institut de formation en éducation physique et en sport dAngers/Les Ponts de Cé | ALL | ADULT | null | 15 | OTHER_GOV | OBSERVATIONAL | Observational Model: |Time Perspective: p | 2012-A01036-37 | 2012-11 | 2014-04 | 2014-04 | 2013-03-01 | null | 2016-02-12 | University Hospital, Angers, 49933, France | null | {} |
NCT02854579 | Neural Progenitor Cell and Paracrine Factors to Treat Hypoxic Ischemic Encephalopathy | https://clinicaltrials.gov/study/NCT02854579 | null | UNKNOWN | The purpose of this study is to investigate the efficacy and safety of allogenic neural progenitor cell and paracrine factors of human mesenchymal stem cells for patients with moderate/severe Hypoxic-Ischemic Encephalopathy | NO | Hypoxic-Ischemic Encephalopathy | BIOLOGICAL: neural progenitor cell|BIOLOGICAL: Paracrine factors|BIOLOGICAL: progenitor cell and paracrine factors | Neonatal Behavioral Neurological Assessment, 14days after birth|number of adverse events, adverse events like fever、infection、seizures、hemorrhage coursed by interventions, 7days after cell or factor injection|Neonatal Behavioral Neurological Assessment, 28days after birth | Bayley score, Gross motor function measure assessment for children diagnosed cerebral palsy, 12 months after birth|Bayley score, Gross motor function measure assessment for children diagnosed cerebral palsy, 18 months after birth|Peabody development measure scale, Gross motor function measure assessment for children di... | null | Navy General Hospital, Beijing | Bethune International Peace Hospital|Daping Hospital and the Research Institute of Surgery of the Third Military Medical University|Hunan Childrens Hospital|Shangluo Central Hospital|252 Military Hospital | ALL | CHILD | null | 120 | OTHER | INTERVENTIONAL | Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: TREATMENT | NavyGHB-P-01 | 2013-01 | 2017-07 | 2017-12 | 2016-08-03 | null | 2016-08-03 | Navy General Hospital, Beijing, Beijing, 100048, China|Navy General Hospital, Beijing, 100048, China | null | {
"neural progenitor cell": [
{
"intervention_type": "BIOLOGICAL"
}
],
"Paracrine factors": [
{
"intervention_type": "BIOLOGICAL"
}
],
"progenitor cell and paracrine factors": [
{
"intervention_type": "BIOLOGICAL"
}
]
} |
NCT02898779 | Metabolism and Pharmacokinetics of Primaquine Enantiomers in Human Volunteers, Study 1 | https://clinicaltrials.gov/study/NCT02898779 | null | COMPLETED | To investigate the comparative tolerability, metabolism and pharmacokinetics of individual enantiomers of PQ in healthy human volunteers. The specific aim is the comparative evaluation of the metabolism, pharmacokinetic behavior, and tolerability of the isomers of PQ (RPQ and SPQ and the racemic mixture RSPQ) in normal... | NO | Malaria | DRUG: Primaquine, R-Primaquine, S-Primaquine, SR Primaquine | Primary outcome: Plasma concentration of parent primaquine and carboyprimaquine following a single dose treatment with primaquine (racemate or enantiomers) not to exceed 45 mg, This study would provide information on differential pharmacokinetics and metabolism of enantiomers of primaquine in normal human volunteers, b... | Area Under Curve (AUC) for primaquine up to 24 hours after the primaquine administration, This study would provide information on differential pharmacokinetics and metabolism of enantiomers of primaquine in normal human volunteers, between 0-24 hours|Maximum concentration (Cmax) for primaquine up to 24 hours after the ... | null | University of Mississippi, Oxford | null | ALL | ADULT | PHASE1 | 36 | OTHER | INTERVENTIONAL | Allocation: RANDOMIZED|Intervention Model: CROSSOVER|Masking: SINGLE (PARTICIPANT)|Primary Purpose: BASIC_SCIENCE | PQ Study 1 | 2017-05-01 | 2018-03-01 | 2018-03-01 | 2016-09-13 | null | 2018-05-15 | University of Mississippi, Oxford, Mississippi, 38677, United States | null | {
"Primaquine": [
{
"intervention_type": "DRUG",
"description": "Primaquine, R-Primaquine, S-Primaquine, SR Primaquine",
"name": "Primaquine",
"synonyms": [
"Primacin",
"Diphosphate, Primaquine",
"Primaquine",
"Primaquin",
"Phosphate, Primaquine",
... |
NCT02840279 | A Multiple Ascending Dose Study of BPN14770 in Healthy Young and Elderly Male or Female Subjects | https://clinicaltrials.gov/study/NCT02840279 | null | COMPLETED | This is a randomized, double-blind (Investigator and subject-blinded) placebo-controlled, multiple, ascending-dose study to evaluate the safety, tolerability, and pharmacokinetic profile of BPN14770 in healthy young and elderly male and female subjects and to provide a preliminary assessment of the cognitive effects of... | NO | Alzheimers Disease | DRUG: BPN14770|DRUG: Placebo | Number of Participants with Adverse Events as a Measure of Safety and Tolerability, Incidence and nature of adverse events (AEs) and serious adverse events (SAEs). Significant assessments reported as AEs or SAEs include clinical laboratory assessments and vital signs, physical and neurological examination, 12-lead elec... | Area Under the Curve from Time Zero to Twelve Hours [AUC0-12], 2 weeks|Area Under the Concentration Time Curve from Zero to 12 Hours, Corrected for Dose [AUC12/D], 2 weeks | ISLT-D, International Shopping List Test words recalled at 24 hours, 2 weeks|GMLT-D, Groton Maze Learning Test errors at 24 hours, 2 weeks | Tetra Discovery Partners | null | ALL | ADULT, OLDER_ADULT | PHASE1 | 77 | INDUSTRY | INTERVENTIONAL | Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: DOUBLE (PARTICIPANT, INVESTIGATOR)|Primary Purpose: TREATMENT | BPN14770-CNS-102 | 2016-06 | 2016-11 | 2016-12 | 2016-07-21 | null | 2017-01-18 | Jasper Clinic, Kalamazoo, Michigan, 49007, United States | null | {
"BPN14770": [
{
"intervention_type": "DRUG"
}
],
"Placebo": [
{
"intervention_type": "DRUG"
}
]
} |
NCT00332579 | Double-Blind Naltrexone in Kleptomania | https://clinicaltrials.gov/study/NCT00332579 | null | COMPLETED | The goal of the proposed study is to evaluate the efficacy and safety of naltrexone in kleptomania. | YES | Kleptomania | DRUG: Naltrexone|DRUG: Placebo | Yale Brown Obsessive Compulsive Scale Modified for Kleptomania (K-YBOCS), The K-YBOCS measures symptom severity (urges/thoughts and behavior) across the past week. Scores range from 0 (no symptoms) to 40 (highest symptom severity)., K-YBOCS is done at each visit by the investigator. | null | null | University of Minnesota | null | ALL | ADULT, OLDER_ADULT | PHASE2 | 25 | OTHER | INTERVENTIONAL | Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: DOUBLE (PARTICIPANT, INVESTIGATOR)|Primary Purpose: TREATMENT | 0602M82626 | 2006-05-01 | 2008-09-01 | 2008-09-01 | 2006-06-01 | 2012-05-04 | 2019-07-29 | University of Minnesota, Minneapolis, Minnesota, 55454, United States | null | {
"Naltrexone": [
{
"intervention_type": "DRUG",
"description": "Naltrexone",
"name": "Naltrexone",
"synonyms": [
"Naltrexona",
"Nalorex",
"Antaxone",
"Celupan",
"N-Cyclopropylmethylnoroxymorphone",
"Naltrexon",
"Nemexin",
"EN... |
NCT03789279 | Observational Study of Hand Function After Distal Transradial Access for Angiography | https://clinicaltrials.gov/study/NCT03789279 | RATATOUILLE | COMPLETED | Traditionally, coronary angiograms are performed through the radial artery which is accessed above the palm of the right hand. In recent years, some cardiologists are performing this procedure from the back of the wrist in as the radial artery courses through the anatomical snuffbox (distal radial access). The aim of t... | NO | Radial Artery Occlusion|Nerve Injury | null | Prevalence of hand dysfunction, Any significant deterioration from baseline in hand function according to the 5 studied domains., 1 month | Success of distal radial access, Successful introduction of sheath, Day 0|Vascular access complications (other than occlusion and bleeding), Surgical complications or clinically important vascular access complications, Day 0|Puncture time, Time from skin puncture to successful placement of wire into the artery, Day 0|R... | null | NHS National Waiting Times Centre Board | MC Zuiderzee | ALL | ADULT, OLDER_ADULT | null | 40 | OTHER | OBSERVATIONAL | Observational Model: |Time Perspective: p | 18-WS-0182|245250 | 2019-01-01 | 2020-12-31 | 2020-12-31 | 2018-12-28 | null | 2021-03-09 | University of Glasgow/Golden Jubilee Research Foundation, Glasgow, G12 8QQ, United Kingdom | null | {} |
NCT02588079 | Internet-Based Cognitive Behavioral Therapy for Children With Dental Anxiety | https://clinicaltrials.gov/study/NCT02588079 | null | COMPLETED | The purpose of this study is to determine whether internet-based cognitive behavioral therapy (ICBT) is effective in the treatment of children and adolescents with dental anxiety. The investigators hypothesis is that children and adolescents who have been offered ICBT show significant better performance on outcome meas... | NO | Dental Anxiety | BEHAVIORAL: Internet-based cognitive behavioral therapy | Picture guided behavioral approach test, child version, Measures changes in self-estimated ability to manage 17 dental situations, showing realistic images from dental care., post treatment(12 weeks), and follow up (12 months after posttreatment)|Picture guided behavioral approach test, parent version, Measures changes... | Self-Efficacy Questionnaire for Phobic Situations ( dentistry adapted version ), Measure changes in childs dentistry related self efficacy, post treatment(12 weeks), and follow up (12 months after posttreatment)|Childrens Fear Survey Schedule - Dental Subscale (child version), Measures changes in the childs dental anxi... | Parental Self-Efficacy Questionnaire for Dental Anxiety, Measure changes in dentistry related parental self efficacy, post treatment(12 weeks), and follow up (12 months after posttreatment)|Childrens Negative Cognitions in Dentistry, Measure changes in childrens dentistry related negative thoughts., post treatment(12 w... | Karolinska Institutet | null | ALL | CHILD | null | 33 | OTHER | INTERVENTIONAL | Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: TREATMENT | KIPED20151008 | 2015-10 | 2023-12-31 | 2023-12-31 | 2015-10-27 | null | 2024-02-14 | Department of Dental Medicine, Stockholm, Huddinge, 14104, Sweden | null | {
"Internet-based cognitive behavioral therapy": [
{
"intervention_type": "BEHAVIORAL"
}
]
} |
NCT00717379 | Study of Tacrolimus Immunosuppressive Therapy After Kidney Transplantation | https://clinicaltrials.gov/study/NCT00717379 | null | COMPLETED | To compare the efficacy and safety of Tacrolimus in combination with MMF and Steroids in two regimens of steroid in an adult kidney transplanted population. | NO | Kidney Transplantation|Kidney Failure, Chronic|Renal Insufficiency, Chronic | DRUG: Tacrolimus|DRUG: Mycophenolate Mofetil|DRUG: Methylprednisolone or equivalent|DRUG: Prednisone | Incidence and time to first biopsy-proven acute rejection, 6 months | Overall frequency of acute rejection episodes within 6 months post transplantation, 6 months|Severity of biopsy proven acute rejections (BANFF criteria) within 6 months post transplantation, 6 months|Incidence of and time to first corticosteroid-resistant acute rejection, 6 months|Subject and graft survival, 6 months | null | Astellas Pharma Inc | null | ALL | ADULT, OLDER_ADULT | PHASE4 | 50 | INDUSTRY | INTERVENTIONAL | Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: TREATMENT | PRG-EC-2R01 | 2007-05 | 2008-10 | 2008-10 | 2008-07-17 | null | 2009-04-15 | Moscow, 115446, Russian Federation|Moscow, 119992, Russian Federation|Moscow, 123182, Russian Federation|Omsk, 644112, Russian Federation|St. Petersburg, 197110, Russian Federation|Volzskii, 404120, Russian Federation | null | {
"Tacrolimus": [
{
"intervention_type": "DRUG",
"description": "Tacrolimus",
"name": "Tacrolimus",
"synonyms": [
"Anhydrous Tacrolimus",
"Tacrolimus, anhydrous",
"FR900506",
"Astagraf XL",
"FR 900506",
"Tacrolimus",
"Prograft",
... |
NCT01294579 | Ofatumumab and Bendamustine Followed by Maintenance Ofatumumab for Rituximab Relapsed Indolent B-cell Non-Hodgkins Lymphoma (B-NHL) | https://clinicaltrials.gov/study/NCT01294579 | null | COMPLETED | The purpose of this phase II open label study was is to evaluate the safety and efficacy of ofatumumab and bendamustine followed by maintenance ofatumumab in subjects with indolent B-NHL who had relapsed after Rituximab treatment. A maximum of 53 subjects at least 18 years old with Small lymphocytic, lymphoplasmacytic,... | YES | Lymphoma, Non-Hodgkin | BIOLOGICAL: Ofatumumab|DRUG: Bendamustine | Complete Remission (CR) Rate of Induction Therapy After Cycle 6 (28 Days) (FAS), Complete response (CR) included all of the following: complete disappearance of all detectable clinical evidence of disease and disease-related symptoms if present before therapy. All target nodes had to have regressed to ≤ 1.5cm in the lo... | Overall Response Rate (ORR) During Induction Phase After Cycle 6 (FAS), The overall response = CR (defined in Primary Outcome) + Partial Response (PR) which required all of the following: > or = to 50% decrease from baseline in target nodules; > or = to 50% decrease in hepatic/splenic nodules and no increase in liver o... | null | Novartis Pharmaceuticals | null | ALL | ADULT, OLDER_ADULT | PHASE2 | 49 | INDUSTRY | INTERVENTIONAL | Allocation: |Intervention Model: |Masking: NONE|Primary Purpose: TREATMENT | 114612 | 2011-05-17 | 2016-12-20 | 2016-12-20 | 2011-02-11 | 2018-08-09 | 2018-08-09 | Novartis Investigative Site, Chandler, Arizona, 85224, United States|Novartis Investigative Site, Burbank, California, 91505, United States|Novartis Investigative Site, Fresno, California, 93720, United States|Novartis Investigative Site, Oxnard, California, 93030, United States|Novartis Investigative Site, Aurora, Col... | null | {
"Ofatumumab": [
{
"intervention_type": "BIOLOGICAL",
"description": "Ofatumumab",
"name": "Ofatumumab",
"synonyms": [
"Arzerra",
"Ofatumumab",
"Kesimpta",
"HuMax-CD20, 2F2",
"Ofatumumabum",
"HuMax-CD20",
"Arzerra",
"Ofatumum... |
NCT05193279 | Safety and Immunogenicity of SCB-2019 in Children <18 Years of Age | https://clinicaltrials.gov/study/NCT05193279 | null | WITHDRAWN | This is a phase 2/3, randomized, controlled study to assess the reactogenicity, safety and immunogenicity of adjuvanted recombinant SARS-CoV-2 trimeric S-protein subunit vaccine (SCB-2019), when administered as 2-dose vaccination series in children below 18 years of age. | NO | COVID-19 | BIOLOGICAL: Candidate vaccine, SCB-2019 | Phase 2, select optimal dose level of SCB-2019 vaccine by age cohort (5-11 years, 2-4 years, and < 2 years), based on safety, Proportion of subjects with solicited local and systemic adverse events, 7 days after dose 1 (Day 1-7)|Phase 2, select optimal dose level of SCB-2019 vaccine by age cohort (5-11 years, 2-4 years... | Phase 3, non-inferiority (SCR difference) of SARS-CoV-2 nAb titers of SCB-2019 vaccine when given to participants 5 to < 12 years as compared to young adults (18 to < 25 years), Proportion of participants achieving seroconversion for SARS-CoV-2 nAb after 2 doses of SCB-2019 vaccine in participants 5 to < 12 years minus... | null | Clover Biopharmaceuticals AUS Pty Ltd | null | ALL | CHILD | PHASE2|PHASE3 | 0 | INDUSTRY | INTERVENTIONAL | Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: QUADRUPLE (PARTICIPANT, CARE_PROVIDER, INVESTIGATOR, OUTCOMES_ASSESSOR)|Primary Purpose: PREVENTION | CLO-SCB-2019-007 | 2022-10-05 | 2022-12-15 | 2022-12-15 | 2022-01-14 | null | 2023-03-24 | Clínica de la Costa Ltda, Barranquilla, 080020, Colombia|Centro de Estudios en Infectología Pediátrica S.A.S. - CEIP S.A.S., Cali, Colombia | null | {
"SCB-2019": [
{
"intervention_type": "BIOLOGICAL",
"description": "Candidate vaccine, SCB-2019",
"name": "SCB-2019",
"synonyms": [
"SCB-2019",
""
],
"drugbank_id": "DB15805",
"generic_names": [
"SCB-2019"
],
"wikipedia_url": "https://... |
NCT00770679 | Effects of Statins on Lower Extremity Arterial Function Assessed by Magnetic Resonance Imaging | https://clinicaltrials.gov/study/NCT00770679 | null | TERMINATED | Cholesterol-lowering drugs called statins improve the functioning of the endothelium, and help prevent heart disease. The investigators are testing whether statins improve endothelial function more in the arteries that have worse endothelium to begin with. One of the functions of the endothelium is to help control how ... | YES | Diabetes | DRUG: lipitor | Mean Change in Low Density Lipoprotein (LDL), Serum LDL, mg/dL (baseline LDL-follow-up LDL), Change from baseline to follow-up, up to 5 weeks|Change in Endothelial Function as Measured on MRI in the Arms, chance from baseline to end of study, up to 5 weeks|Change in Endothelial Function as Measured on MRI in the Legs, ... | null | null | Johns Hopkins University | Pfizer | ALL | ADULT, OLDER_ADULT | null | 16 | OTHER | INTERVENTIONAL | Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: DIAGNOSTIC | NA00002253 | 2008-06 | 2012-07 | 2012-07 | 2008-10-10 | 2017-09-13 | 2017-09-13 | Harry SIlber, MD, Baltimore, Maryland, 21224, United States | null | {
"Atorvastatin": [
{
"intervention_type": "DRUG",
"description": "lipitor",
"name": "Atorvastatin",
"synonyms": [
"atorvastatine",
"Atorvastatin Calcium Anhydrous",
"Atorvastatin Calcium Trihydrate",
"Atorvastatin Calcium",
"Sortis",
"atorva... |
NCT01990079 | Use of Technological Advances to Prevent Smoking Relapse Among Smokers With PTSD | https://clinicaltrials.gov/study/NCT01990079 | QUIT4EVER | COMPLETED | The primary goal of the study is to evaluate the use of a new smart phone application in preventing relapse to smoking among people with PTSD. The technology intervention will combine a mobile system to reward non-smoking, smoking cessation counseling, smoking cessation medications, and use of the smart phone app. The ... | NO | PTSD|Smoking | DRUG: Bupropion|DRUG: nicotine replacement therapy|OTHER: Smoking cessation counseling|BEHAVIORAL: mobile contingency management|OTHER: Stay Quit Coach | smoking, self-report, Participants self-report of smoking in the past seven days will be measured at the end of the treatment intervention, and at 3 and 6-month follow-up contacts., 6 months follow-up | saliva cotinine, For participants reporting smoking abstinence at 3 and 6-months post treatment follow-ups, we will bio-verify smoking abstinence by collecting saliva samples that will be used to determine salivary cotinine levels., 6 months | null | Duke University | null | ALL | ADULT, OLDER_ADULT | null | 15 | OTHER | INTERVENTIONAL | Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: TREATMENT | Pro00048990 | 2013-12 | 2015-08 | 2015-08 | 2013-11-21 | null | 2015-09-17 | Duke University Medical Center, Durham, North Carolina, 27706, United States | null | {
"Bupropion": [
{
"intervention_type": "DRUG",
"description": "Bupropion",
"name": "Bupropion",
"synonyms": [
"Bupropion",
"Bupropion Hydrochloride",
"Forfivo",
"Bupropion, (+-)-Isomer",
"Amfebutamone",
"Quomen",
"Zyntabac",
... |
End of preview. Expand in Data Studio
No dataset card yet
- Downloads last month
- 20